Latest Nova Eye Medical (ASX:EYE) News

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.